Vaccines

Heterologous vaccine intervention (HVI), receiving immune-boosting vaccinations other than a COVID-19 shot, may alleviate COVID-19 case burdens.

The AIDS Clinical Trials Group (ACTG) is beginning stage 2 trials for Triplex, a novel vaccine for people living with HIV and cytomegalovirus (CMV).

Breastfeeding babies safely receive COVID-19-neutralizing antibodies from their mRNA-vaccinated mothers.

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

The CDC recommends all pregnant women receive a COVID-19 vaccine, finding vaccination does not increase risk of preterm birth or small-for-gestational-age at birth.

A new study found states that offered monetary prizes to randomly selected vaccinated persons did not have significant increases in vaccine uptake.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Antimicrobial resistance is “the silent pandemic,” Dr. Leonard Friedland says, and vaccines are how we fight it.

A personal history of cervical cancer or cervical biopsy did not make mothers more likely to vaccinate their children against HPV.

HPV vaccination decreases cervical cancer incidence and mortality, but it is most effective in young women and girls.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.

COVID-19 vaccines are frequently tested in low- and middle-income countries, but they have experienced significant delays in vaccinating their own populations.

In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.

Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.

2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.